https://pepsreview.com/articles/retatrutide-beats-ozempic-transcend-t2d-2-phase-3-diabetes PepsReview en 2026-10-28 retatrutide, Ozempic, semaglutide, TRANSCEND-T2D-2, type 2 diabetes, GLP-1 triple agonist, Eli Lilly, peptide research https://pepsreview.com/articles/psm-citizen-petition-fda-block-peptide-compounding PepsReview en 2026-10-28 peptide compounding, FDA citizen petition, 503A bulks list, BPC-157, TB-500, PCAC, peptide regulation https://pepsreview.com/articles/tradipitant-phase-3-glp1-vomiting-severe-cases-vanda-snda PepsReview en 2026-10-27 tradipitant, NEREUS, GLP-1 vomiting, semaglutide side effects, NK-1 antagonist, Vanda Pharmaceuticals, GLP-1 tolerability, FDA sNDA https://pepsreview.com/articles/novo-nordisk-injunction-denied-lilly-glp1-advertising-ruling PepsReview en 2026-10-27 Novo Nordisk, Eli Lilly, GLP-1 advertising, false advertising lawsuit, Zepbound, Wegovy, preliminary injunction, direct-to-consumer pharma ads https://pepsreview.com/articles/lilly-eloratzp-amplify-phase-3-trials-titration-tolerability PepsReview en 2026-10-27 EloraTZP, eloralintide, Eli Lilly, amylin agonist, Phase 3 trial, AMPLIFY-1, tirzepatide, obesity drug pipeline https://pepsreview.com/articles/corxel-spac-merger-377m-oral-glp1-cx11-phase-3 PepsReview en 2026-10-27 Corxel Pharmaceuticals, CX11, oral GLP-1, SPAC merger, Amanat Acquisition Corp, obesity drug pipeline, Phase 3 trial, oral semaglutide competition https://pepsreview.com/articles/oral-semaglutide-uptake-nears-injectable-levels-epic-study PepsReview en 2026-10-26 oral semaglutide, GLP-1, JAMA Network Open, Epic Cosmos, tirzepatide, weight management, obesity medication, telehealth https://pepsreview.com/articles/compounding-pharmacy-fails-revive-glp1-antitrust-case-lilly-novo PepsReview en 2026-10-26 GLP-1, antitrust, Eli Lilly, Novo Nordisk, compounding pharmacy, Strive Specialties, telehealth, enforcement